Printer Friendly

PAUL R. DAWSON, AMGEN VICE PRESIDENT OF SALES AND MARKETING

 PAUL R. DAWSON, AMGEN VICE PRESIDENT OF SALES AND MARKETING
 THOUSAND OAKS, Calif., Feb. 21 /PRNewswire/ -- With deepest regrets, Amgen (NASDAQ: AMGN) today announced the death of Paul R. Dawson, Amgen's Vice President, Sales and Marketing.
 Mr. Dawson passed away today at the Denver Presbyterian Hospital, Denver, Colo., where he was being treated as the result of a cardiac arrest that occurred the evening of Monday, Feb. 17.
 "It is difficult to express the sorrow and sense of loss that all of us at Amgen feel," said Chairman and Chief Executive Officer Gordon Binder. "Paul's contributions to Amgen are considerable -- he set the framework for a highly respected, selling organization that has successfully launched two of biotechnology's most valuable products. He was instrumental in the creation and expansion of an excellent marketing organization, an organization that is staffed with people committed to providing patients and their providers with quality therapeutic products, education and support. We will miss Paul's talents, integrity and thoughtful contributions as we face the challenges ahead. All of Amgen's thoughts and prayers are with his family."
 Thomas D. Beard, Vice President, Sales will manage the sales and marketing organization in the interim. "Paul built a strong organization that is staffed by competent professionals," commented Binder. "I am confident that Tommy and all members of this organization will continue to achieve the level of excellence our patients and medical care providers have come to expect."
 Amgen Inc. (NASDAQ: AMGN) is an international pharmaceutical company that develops, manufactures and markets human pharmaceuticals based on advanced cellular and molecular biology.
 -0- 2/22/92
 /CONTACT: Sarah H. Crampton, 805-499-5725, ext. 3250 (office) or 805-499-4727 (home); or Kimberly L. Dorsey, 805-499-5725, ext. 4367 (office) or 805-373-6161 (home), both of Amgen/
 (AMGN) CO: Amgen Inc. ST: California IN: MTC SU: PER


KJ -- LA022 -- 1620 02/21/92 21:10 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 21, 1992
Words:308
Previous Article:HONEY HILL FARMS FROZEN YOGURT MIX RECALLED
Next Article:HONEY HILL FARMS ANNOUNCES VOLUNTARY RECALL OF FROZEN YOGURT
Topics:


Related Articles
AMGEN EXPECTS ACCELERATED GROWTH IN 2002 FINANCIAL RESULTS.
Amgen Appoints Industry Veteran Dr. David R. Parkinson To Head Oncology Clinical Development.
ARYx Therapeutics Appoints Former Amgen Exec to Board.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters